{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "T cells",
      "coronavirus",
      "immune responses"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32935333",
  "DateCompleted": {
    "Year": "2020",
    "Month": "12",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "10",
        "Day": "27"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1111/imm.13262"
    ],
    "Journal": {
      "ISSN": "1365-2567",
      "JournalIssue": {
        "Volume": "162",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Immunology",
      "ISOAbbreviation": "Immunology"
    },
    "ArticleTitle": "T-cell responses and therapies against SARS-CoV-2 infection.",
    "Pagination": {
      "StartPage": "30",
      "EndPage": "43",
      "MedlinePgn": "30-43"
    },
    "Abstract": {
      "AbstractText": [
        "Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus strain. Some studies suggest that COVID-19 could be an immune-related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue damage, leading to worse disease outcomes. T cells can act as a double-edge sword with both pro- and anti-roles in the progression of COVID-19. Thus, better understanding of their roles in immune responses to SARS-CoV-2 infection is crucial. T cells primarily react to the spike protein on the coronavirus to initiate antiviral immunity; however, T-cell responses can be suboptimal, impaired or excessive in severe COVID-19 patients. This review focuses on the multifaceted roles of T cells in COVID-19 pathogenesis and rationalizes their significance in eliciting appropriate antiviral immune responses in COVID-19 patients and unexposed individuals. In addition, we summarize the potential therapeutic approaches related to T cells to treat COVID-19 patients. These include adoptive T-cell therapies, vaccines activating T-cell responses, recombinant cytokines, Th1 activators and Th17 blockers, and potential utilization of immune checkpoint inhibitors alone or in combination with anti-inflammatory drugs to improve antiviral T-cell responses against SARS-CoV-2."
      ],
      "CopyrightInformation": "\u00a9 2020 The Authors. Immunology published by John Wiley & Sons Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-4683-3329"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), P.O. Box: 34110, Doha, Qatar."
          }
        ],
        "LastName": "Toor",
        "ForeName": "Salman M",
        "Initials": "SM"
      },
      {
        "Identifier": [
          "0000-0002-8292-1895"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), P.O. Box: 34110, Doha, Qatar."
          }
        ],
        "LastName": "Saleh",
        "ForeName": "Reem",
        "Initials": "R"
      },
      {
        "Identifier": [
          "0000-0001-5047-2338"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), P.O. Box: 34110, Doha, Qatar."
          }
        ],
        "LastName": "Sasidharan Nair",
        "ForeName": "Varun",
        "Initials": "V"
      },
      {
        "Identifier": [
          "0000-0001-6119-8389"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), P.O. Box: 34110, Doha, Qatar."
          }
        ],
        "LastName": "Taha",
        "ForeName": "Rowaida Z",
        "Initials": "RZ"
      },
      {
        "Identifier": [
          "0000-0002-3868-0318"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), P.O. Box: 34110, Doha, Qatar."
          },
          {
            "Identifier": [],
            "Affiliation": "Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, UK."
          }
        ],
        "LastName": "Elkord",
        "ForeName": "Eyad",
        "Initials": "E"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Immunology",
    "NlmUniqueID": "0374672",
    "ISSNLinking": "0019-2805"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunologic Factors"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adoptive Transfer"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "immunology",
        "therapy",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Immunity, Cellular"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Immunologic Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "virology"
      ],
      "DescriptorName": "Lung"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "transplantation",
        "virology"
      ],
      "DescriptorName": "T-Lymphocytes"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}